金属硫蛋白过表达对乳腺癌化疗方案选择的影响(英文)

Effect of Metallothionein Over-expression for the Chemotherapy Scheme of Breast Cancer

目的:探讨金属硫蛋白(Metallothionein,MT)在乳腺癌中过表达的意义及其与乳腺癌化疗方案选择的相关性。方法:利用SP免疫组织化学技术,检测88例乳腺癌组织中MT表达率。结果:MT在乳腺癌中总阳性率为67.05%(59/88)。MT在髓样癌、小叶癌和导管癌中的阳性率分别为41.67%,85.71%和62.50%。在浸润型乳腺癌组阳性率明显高于非浸润型癌组(P<0.05);在小叶癌组阳性率高于髓样癌组和导管癌组(P<0.05);淋巴结转移组阳性率高于非转移组(P<0.05)。结论:MT表达与乳腺癌的病理类型及有否淋巴结转移相关,检测MT对乳腺癌化疗方案的制定有指导意义。

Objective ：To study the significance of metallothionein（MT）over-expressionin breast cancer and the relationship between chemotherapy scheme and the expression of MT.Methods ：Sp immunohistochemical method was used to examine the expression rate of MTin 88 cases with breast cancer.Results ：The total positive rate of MT was 67.05 %（59/88） in breast cancer.The positive rates of MT were 41.67 %,85.71 % and 62.50 %in marrow cancer,lobular cancer and ductal cancer respectively.The positive rate of MTin lobular cancer was significantly higher thanthat in medullary and ductal cancers（P〈0.05）.The positive rate of MT in infiltrating type cancer was higher than that with no-infiltrating.The positive rates for lymph node metastasis group were higher thanthat of non-lymph node metastasis group（P〈0.05）.Conclusion ：The expression of MT is related to pathology type and Lymph metastasis and it is a guidance for clinical choice for chemotherapy scheme.